TOKYO -- Japanese pharmaceutical companies are ramping up efforts to develop cures for rare diseases. Progress in digital technology and generous government financial support are making such drugs increasingly lucrative.
Fujifilm Holdings and Takeda Pharmaceutical are two of the drugmakers that are seeking to grow their business of selling costly drugs for rare conditions. The market for these so-called orphan drugs will be worth $200 billion in 2022, according to an estimate by a British research company.
By continuing to browse this website, you accept cookies which are used for several reasons such as personalizing content/ads and analyzing how this website is used. Please review our
to learn how you can update your cookie settings.